NJ High Court Won't Disturb Novartis Bone Drug Win
Law360, New York (November 7, 2012, 6:35 PM EST) -- The New Jersey Supreme Court has declined to hear a challenge to judgments for Novartis Pharmaceuticals Corp. in the first bellwether trial in consolidated litigation over claims the drugmaker's bone cancer drugs Aredia and Zometa caused jaw deterioration.
The high court denied certification for the case, in which the state's appeals division had backed key lower-court rulings against plaintiff Jane Bessemer's direct-to-consumer advertising claims and failure-to-warn allegations. The certification order was filed Oct. 25 and publicly released earlier this month.
In June, a three-judge appeals panel agreed that the direct-to-consumer advertising exception to the so-called learned intermediary doctrine did not apply...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!